Olezarsen vs Plozasiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Familial Chylomicronemia Syndrome
Shared mechanism: APOC3 · full Familial Chylomicronemia Syndrome pipeline
Olezarsen · Tryngolza
Marketed by Ionis Pharmaceuticals and partners
NCT04568434 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 66 patients with a rare disease. Of its two primary comparisons, olezarsen 80 mg lowered triglycerides significantly more than placebo at 6 months (p=0.0009), but olezarsen 50 mg did not (p=0.0775), so the primary result was only partly met.
Next expected readout: June 2027 · NCT05185843 (registry estimate)
Reported efficacy
Percent Change From Baseline in Fasting TG at Month 6: Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53. (mixed)
Result source: NCT04568434
Plozasiran · Redemplo
Marketed by Arrowhead Pharmaceuticals and partners
NCT05089084 · Phase 3 · completed
The study randomly assigned 75 participants to plozasiran or placebo and used quadruple masking, with 25 mg, 50 mg, and pooled placebo groups. The primary fasting-triglyceride endpoint was statistically significantly improved for both doses, but it was a laboratory surrogate rather than a hard clinical or endoscopic outcome, supporting a moderate grade.
Reported efficacy
Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): ARO-APOC3 (Plozasiran) 25 mg -80.1% (IQR -89.9 to -61) | ARO-APOC3 (Plozasiran) 50 mg -77.6% (IQR -87.7 to -48.6) vs Placebo (Pooled) -17.1% (IQR -49.1 to 47) (met)
Result source: NCT05089084
Results for Familial Chylomicronemia Syndrome
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Plozasiran
show 5 more results
show 3 more results
show 3 more results
Available safety results
Plozasiran
| Dropout rate | 11.5%25 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 show 1 more result8.3%50 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 |
|---|---|
| Discontinued due to AEs | 7.7%25 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 show 1 more result4.2%50 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 |
| Serious AEs | 19.2%25 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 show 1 more result8.3%50 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 |
| Most frequent reported AEs | 25 mg abdominal pain 26.9% (placebo 28%) covid-19 19.2% (placebo 4%) nasopharyngitis 19.2% (placebo 16%) NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 show 1 more result50 mg abdominal pain 29.2% (placebo 28%) covid-19 29.2% (placebo 4%) headache 20.8% (placebo 8%) NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 |
Severe Hypertriglyceridemia
Shared mechanism: APOC3 · full Severe Hypertriglyceridemia pipeline
Olezarsen · Tryngolza
Marketed by Ionis Pharmaceuticals and partners
NCT05079919 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled trial of 617 patients. Both tested doses of olezarsen produced large reductions in triglycerides, the physiological measure that defines this disease, compared with placebo, with strong statistical significance.
Next expected readout: March 2027 · NCT05681351 (registry estimate)
Reported efficacy
Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6): Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) (met)
Result source: NCT05552326
Plozasiran · Redemplo
Marketed by Arrowhead Pharmaceuticals and partners
NCT06347003 · Phase 3 · completed
This was a randomized, quadruple-masked Phase 3 trial with 446 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-07-22. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Next expected readout: March 2029 · NCT06880770 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Severe Hypertriglyceridemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Olezarsen: 8 of 9 rows · Plozasiran: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olezarsen | Plozasiran |
|---|---|---|
| Apo B percent change · % of baseline | -11.67% (n=58) vs 0.68% (n=39) placebo @ 52wk50 mga,b,c,d NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more dose-18.53% (n=57) vs 0.68% (n=39) placebo @ 52wk80 mg NCT05355402 · Phase 2 · registry result, not featured evidence | 2.4% (n=57) vs 5.7% (n=60) placebo @ 48wk50 mga,b,c,d NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more doses-0.2% (n=55) vs 5.7% (n=60) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 6.4% (n=54) vs 5.7% (n=60) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Apo C3 percent change · % of baseline | -69.09% (n=58) vs -12.4% (n=39) placebo @ 52wk50 mga,b,c,d NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more dose-83.78% (n=57) vs -12.4% (n=39) placebo @ 52wk80 mg NCT05355402 · Phase 2 · registry result, not featured evidence | -48.3% (n=57) vs 135.8% (n=60) placebo @ 48wk50 mga,b,c,d NCT04720534 · Phase 2 · registry result, not featured evidence show 5 more doses-46.8% (n=57) vs 5.6% (n=57) placebo @ 48wk50 mg NCT04720534 · Phase 2 · registry result, not featured evidence -49.6% (n=55) vs 135.8% (n=60) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence -48% (n=55) vs 5.6% (n=57) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence -34.5% (n=54) vs 135.8% (n=60) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence -33.7% (n=53) vs 5.6% (n=57) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Fasting TG percent change · % of baseline | -51.67% (n=58) vs -5.59% (n=39) placebo @ 52wk50 mga,b,c,d NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more dose-60.39% (n=57) vs -5.59% (n=39) placebo @ 52wk80 mg NCT05355402 · Phase 2 · registry result, not featured evidence | -53.4% (n=57) vs -6.6% (n=60) placebo @ 48wk50 mga,b,c,d NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more doses-58% (n=55) vs -6.6% (n=60) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence -31.4% (n=54) vs -6.6% (n=60) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| HDL-C percent change · % of baseline | 54.2% (n=58) vs 10.53% (n=39) placebo @ 52wk50 mga,b,c,d NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more dose57.43% (n=57) vs 10.53% (n=39) placebo @ 52wk80 mg NCT05355402 · Phase 2 · registry result, not featured evidence | 37.8% (n=57) vs 6.1% (n=60) placebo @ 48wk50 mga,b,c,d NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more doses32.4% (n=55) vs 6.1% (n=60) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 23.5% (n=54) vs 6.1% (n=60) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Non-HDL-C percent change · % of baseline | -20% (n=58) vs -2.55% (n=39) placebo @ 52wk50 mga,b,c,d NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more dose-26.57% (n=57) vs -2.55% (n=39) placebo @ 52wk80 mg NCT05355402 · Phase 2 · registry result, not featured evidence | -13.5% (n=57) vs 0.5% (n=60) placebo @ 48wk50 mga,b,c,d NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more doses-23% (n=55) vs 0.5% (n=60) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence -10% (n=54) vs 0.5% (n=60) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 12.1%50 mge NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more result8.8%80 mg NCT05355402 · Phase 2 · registry result, not featured evidence | 7%50 mge NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more results5.5%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 9.1%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —50 mge NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more result—80 mg NCT05355402 · Phase 2 · registry result, not featured evidence | 1.8%50 mge NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more results0%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 1.8%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 10.3%50 mge NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more result14%80 mg NCT05355402 · Phase 2 · registry result, not featured evidence | 12.5%50 mge NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more results3.6%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 7.4%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 50 mge injection site erythema 13.8% (placebo 0%) fatigue 10.3% (placebo 2.6%) urinary tract infection 10.3% (placebo 15.4%) NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more result80 mg covid-19 7% (placebo 5.1%) diabetes mellitus 7% (placebo 2.6%) acute sinusitis 5.3% (placebo 2.6%) NCT05355402 · Phase 2 · registry result, not featured evidence | 50 mge covid-19 16.1% (placebo 14.8%) upper respiratory tract infection 12.5% (placebo 6.6%) type 2 diabetes mellitus 10.7% (placebo 4.9%) NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more results25 mg covid-19 16.4% (placebo 14.8%) headache 10.9% (placebo 4.9%) sinusitis 7.3% (placebo 0%) NCT04720534 · Phase 2 · registry result, not featured evidence 10 mg covid-19 20.4% (placebo 14.8%) headache 14.8% (placebo 4.9%) urinary tract infection 11.1% (placebo 9.8%) NCT04720534 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 48 weeks versus 52 weeks.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olezarsen
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
Hypertriglyceridemia
Shared mechanism: APOC3 · full Hypertriglyceridemia pipeline
Olezarsen · Tryngolza
Marketed by Ionis Pharmaceuticals and partners
NCT05610280 · Phase 3 · completed
Essence-TIMI 73b was a large, randomized, double-blind, placebo-controlled trial in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, or with severe hypertriglyceridemia. The primary outcome was the placebo-adjusted percent change in triglycerides from baseline to 6 months in the moderate-hypertriglyceridemia population (1,349 patients). Triglycerides fell by 58.4 percentage points more than placebo with olezarsen 50 mg and by 60.6 percentage points more with 80 mg (P<0.001 for both), so the primary endpoint was met at both doses. The figures come from the peer-reviewed paper (N Engl J Med 2025).
Next expected readout: March 2027 · NCT05681351 (registry estimate)
Reported efficacy
Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6): Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) (met)
Result source: NCT05552326
Plozasiran · Redemplo
Marketed by Arrowhead Pharmaceuticals and partners
NCT06347003 · Phase 3 · completed
This was a randomized, quadruple-masked Phase 3 trial with 446 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-07-22. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Next expected readout: July 2028 · NCT06822790 (registry estimate)
Reported efficacy
Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo (Baseline, Month 12): Primary endpoint met: triglyceride reduction vs placebo, and all prespecified secondary endpoints (SHASTA-3, Arrowhead, 2026-07-22). (met)
Result source: NCT06347003
Results for Hypertriglyceridemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Olezarsen: 9 of 9 rows · Plozasiran: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olezarsen | Plozasiran |
|---|---|---|
| Apo B percent change · % of baseline | -18.53% (n=57) vs 0.68% (n=39) placebo @ 52wk80 mga,b,c,d NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more dose-11.67% (n=58) vs 0.68% (n=39) placebo @ 52wk50 mg NCT05355402 · Phase 2 · registry result, not featured evidence | 2.4% (n=57) vs 5.7% (n=60) placebo @ 48wk50 mga,b,c,d NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more doses-0.2% (n=55) vs 5.7% (n=60) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 6.4% (n=54) vs 5.7% (n=60) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Apo C3 percent change · % of baseline | -83.78% (n=57) vs -12.4% (n=39) placebo @ 52wk80 mga,b,c,d NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more dose-69.09% (n=58) vs -12.4% (n=39) placebo @ 52wk50 mg NCT05355402 · Phase 2 · registry result, not featured evidence | -48.3% (n=57) vs 135.8% (n=60) placebo @ 48wk50 mga,b,c,d NCT04720534 · Phase 2 · registry result, not featured evidence show 5 more doses-46.8% (n=57) vs 5.6% (n=57) placebo @ 48wk50 mg NCT04720534 · Phase 2 · registry result, not featured evidence -49.6% (n=55) vs 135.8% (n=60) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence -48% (n=55) vs 5.6% (n=57) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence -34.5% (n=54) vs 135.8% (n=60) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence -33.7% (n=53) vs 5.6% (n=57) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Fasting TG percent change · % of baseline | -60.39% (n=57) vs -5.59% (n=39) placebo @ 52wk80 mga,b,c,d NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more dose-51.67% (n=58) vs -5.59% (n=39) placebo @ 52wk50 mg NCT05355402 · Phase 2 · registry result, not featured evidence | -53.4% (n=57) vs -6.6% (n=60) placebo @ 48wk50 mga,b,c,d NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more doses-58% (n=55) vs -6.6% (n=60) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence -31.4% (n=54) vs -6.6% (n=60) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| HDL-C percent change · % of baseline | 57.43% (n=57) vs 10.53% (n=39) placebo @ 52wk80 mga,b,c,d NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more dose54.2% (n=58) vs 10.53% (n=39) placebo @ 52wk50 mg NCT05355402 · Phase 2 · registry result, not featured evidence | 37.8% (n=57) vs 6.1% (n=60) placebo @ 48wk50 mga,b,c,d NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more doses32.4% (n=55) vs 6.1% (n=60) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 23.5% (n=54) vs 6.1% (n=60) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Non-HDL-C percent change · % of baseline | -26.57% (n=57) vs -2.55% (n=39) placebo @ 52wk80 mga,b,c,d NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more dose-20% (n=58) vs -2.55% (n=39) placebo @ 52wk50 mg NCT05355402 · Phase 2 · registry result, not featured evidence | -13.5% (n=57) vs 0.5% (n=60) placebo @ 48wk50 mga,b,c,d NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more doses-23% (n=55) vs 0.5% (n=60) placebo @ 48wk25 mg NCT04720534 · Phase 2 · registry result, not featured evidence -10% (n=54) vs 0.5% (n=60) placebo @ 48wk10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 8.8%80 mge NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results12.1%50 mg NCT05355402 · Phase 2 · registry result, not featured evidence 0%50 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 13%15 mg Q2W NCT03385239 · Phase 2 · registry result, not featured evidence 13.6%10 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 17.4%10 mg QW NCT03385239 · Phase 2 · registry result, not featured evidence | 7%50 mge NCT04720534 · Phase 2 · registry result, not featured evidence show 6 more results5.5%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 9.1%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence 7.6%50 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 7.6%50 mg Q24W NCT04998201 · Phase 2 · registry result, not featured evidence 4.5%25 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 10.4%10 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —80 mge NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results—50 mg NCT05355402 · Phase 2 · registry result, not featured evidence 0%50 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 4.3%15 mg Q2W NCT03385239 · Phase 2 · registry result, not featured evidence 0%10 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 0%10 mg QW NCT03385239 · Phase 2 · registry result, not featured evidence | 1.8%50 mge NCT04720534 · Phase 2 · registry result, not featured evidence show 6 more results0%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 1.8%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence 0%50 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 1.5%50 mg Q24W NCT04998201 · Phase 2 · registry result, not featured evidence 0%25 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 1.5%10 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 14%80 mge NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results10.3%50 mg NCT05355402 · Phase 2 · registry result, not featured evidence 13.6%50 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 17.4%15 mg Q2W NCT03385239 · Phase 2 · registry result, not featured evidence 13.6%10 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 4.3%10 mg QW NCT03385239 · Phase 2 · registry result, not featured evidence | 12.5%50 mge NCT04720534 · Phase 2 · registry result, not featured evidence show 6 more results3.6%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 7.4%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence 10.6%50 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 7.6%50 mg Q24W NCT04998201 · Phase 2 · registry result, not featured evidence 7.5%25 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 3%10 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 80 mge covid-19 7% (placebo 5.1%) diabetes mellitus 7% (placebo 2.6%) acute sinusitis 5.3% (placebo 2.6%) NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results50 mg injection site erythema 13.8% (placebo 0%) fatigue 10.3% (placebo 2.6%) urinary tract infection 10.3% (placebo 15.4%) NCT05355402 · Phase 2 · registry result, not featured evidence 50 mg Q4W injection site erythema 18.2% (placebo 0%) nasopharyngitis 18.2% (placebo 12.5%) nausea 18.2% (placebo 4.2%) NCT03385239 · Phase 2 · registry result, not featured evidence 15 mg Q2W nasopharyngitis 17.4% (placebo 12.5%) arthralgia 13% (placebo 0%) dizziness 13% (placebo 0%) NCT03385239 · Phase 2 · registry result, not featured evidence 10 mg Q4W anaemia 13.6% (placebo 0%) arthralgia 13.6% (placebo 0%) back pain 13.6% (placebo 4.2%) NCT03385239 · Phase 2 · registry result, not featured evidence 10 mg QW injection site erythema 21.7% (placebo 0%) nasopharyngitis 21.7% (placebo 12.5%) upper respiratory tract infection 17.4% (placebo 12.5%) NCT03385239 · Phase 2 · registry result, not featured evidence | 50 mge covid-19 16.1% (placebo 14.8%) upper respiratory tract infection 12.5% (placebo 6.6%) type 2 diabetes mellitus 10.7% (placebo 4.9%) NCT04720534 · Phase 2 · registry result, not featured evidence show 6 more results25 mg covid-19 16.4% (placebo 14.8%) headache 10.9% (placebo 4.9%) sinusitis 7.3% (placebo 0%) NCT04720534 · Phase 2 · registry result, not featured evidence 10 mg covid-19 20.4% (placebo 14.8%) headache 14.8% (placebo 4.9%) urinary tract infection 11.1% (placebo 9.8%) NCT04720534 · Phase 2 · registry result, not featured evidence 50 mg Q12W covid-19 13.6% (placebo 13.8%) type 2 diabetes mellitus 12.1% (placebo 4.6%) urinary tract infection 9.1% (placebo 8%) NCT04998201 · Phase 2 · registry result, not featured evidence 50 mg Q24W type 2 diabetes mellitus 16.7% (placebo 4.6%) upper respiratory tract infection 13.6% (placebo 8%) covid-19 9.1% (placebo 13.8%) NCT04998201 · Phase 2 · registry result, not featured evidence 25 mg Q12W covid-19 16.4% (placebo 13.8%) upper respiratory tract infection 10.4% (placebo 8%) urinary tract infection 9% (placebo 8%) NCT04998201 · Phase 2 · registry result, not featured evidence 10 mg Q12W covid-19 11.9% (placebo 13.8%) type 2 diabetes mellitus 7.5% (placebo 4.6%) bronchitis 6% (placebo 1.1%) NCT04998201 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 48 weeks versus 52 weeks.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olezarsen
show 7 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 5 more results
Plozasiran
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olezarsen's landscape · Plozasiran's landscape